Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Leuprorelin

Hormonal & Reproductive

Molecular Dossier

  • Rank Index: 69
  • Status: FDA Approved
  • What does this mean?
  • Molecular Structure: MW: 1,209.4 Da | Formula: C₅₉H₈₄N₁₆O₁₂ | CAS: 53714-56-0 | Sequence: pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

About Leuprorelin

Leuprorelin (leuprolide acetate; brand names Lupron, Eligard, Prostap) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), FDA-approved since 1985. It is one of the most clinically significant peptides in endocrinology. Paradoxically, while GnRH pulses stimulate LH and FSH release, continuous leuprorelin administration downregulates GnRH receptors on pituitary gonadotrophs — causing a profound and reversible suppression of LH, FSH, and downstream sex hormones (testosterone in males, estrogen in females). In men, castration-level testosterone (<50 ng/dL) is achieved within 2–4 weeks. Clinical indications include prostate cancer (androgen deprivation therapy), endometriosis, uterine fibroids, central precocious puberty, and gender-affirming hormone therapy. In the longevity and performance research space, leuprorelin is studied as a tool for temporary HPG axis suppression followed by controlled restart — relevant to post-cycle protocols and hypothalamic reset in hypogonadism models. A Phase 2 immunological study (TRIIM trial, 2019) used leuprorelin as part of a multi-drug regimen that appeared to reverse epigenetic aging by approximately 2.5 years in a small cohort, generating significant longevity research interest. Available as 1-month, 3-month, 4-month, and 6-month depot formulations, as well as daily SC injection. Side effects of sustained use include hot flashes, bone mineral density loss, and cardiovascular risk consistent with hypogonadal state.

Clinical Focus

GnRH Agonist — Testosterone Suppression & Hormonal Axis Reset

Archival Aliases

Leuprolide acetate, Lupron, Eligard, Prostap, Enantone

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 1,209.4 Da | Formula: C₅₉H₈₄N₁₆O₁₂ | CAS: 53714-56-0 | Sequence: pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt
Primary Pathway Hormonal & Reproductive
Research Phase FDA Approved

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov
[REF 3] ncbi.nlm.nih.gov

Data Verified: 2026-04-22

Synergistic Matrix